These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 20736067

  • 1. L-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata.
    Rangel-Barajas C, Silva I, Lopéz-Santiago LM, Aceves J, Erlij D, Florán B.
    Neurobiol Dis; 2011 Jan; 41(1):51-61. PubMed ID: 20736067
    [Abstract] [Full Text] [Related]

  • 2. 6-OHDA-induced hemiparkinsonism and chronic L-DOPA treatment increase dopamine D1-stimulated [(3)H]-GABA release and [(3)H]-cAMP production in substantia nigra pars reticulata of the rat.
    Rangel-Barajas C, Silva I, García-Ramírez M, Sánchez-Lemus E, Floran L, Aceves J, Erlij D, Florán B.
    Neuropharmacology; 2008 Oct; 55(5):704-11. PubMed ID: 18588904
    [Abstract] [Full Text] [Related]

  • 3. Subchronic administration of L-DOPA to adult rats with a unilateral 6-hydroxydopamine lesion of dopamine neurons results in a sensitization of enhanced GABA release in the substantia nigra, pars reticulata.
    Yamamoto N, Pierce RC, Soghomonian JJ.
    Brain Res; 2006 Dec 06; 1123(1):196-200. PubMed ID: 17027936
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels.
    Mela F, Marti M, Bido S, Cenci MA, Morari M.
    Neurobiol Dis; 2012 Jan 06; 45(1):573-82. PubMed ID: 22001605
    [Abstract] [Full Text] [Related]

  • 7. L-DOPA-induced modulation of GABA and glutamate release in substantia nigra pars reticulata in a rodent model of Parkinson's disease.
    Ochi M, Shiozaki S, Kase H.
    Synapse; 2004 May 06; 52(2):163-5. PubMed ID: 15034922
    [No Abstract] [Full Text] [Related]

  • 8. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
    Carta M, Lindgren HS, Lundblad M, Stancampiano R, Fadda F, Cenci MA.
    J Neurochem; 2006 Mar 06; 96(6):1718-27. PubMed ID: 16539687
    [Abstract] [Full Text] [Related]

  • 9. An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
    Spinnewyn B, Charnet C, Cornet S, Roubert V, Chabrier PE, Auguet M.
    Fundam Clin Pharmacol; 2011 Oct 06; 25(5):608-18. PubMed ID: 21077938
    [Abstract] [Full Text] [Related]

  • 10. Striatal dopaminergic fiber recovery after acute L-DOPA treatment in 6-hydroxydopamine (6-OHDA) lesioned rats.
    Fang C, Yin J, Xu Z, Wang Y, Xu H, Zhou H, Gao C.
    Cell Biochem Biophys; 2011 Jan 06; 59(1):49-56. PubMed ID: 20714825
    [Abstract] [Full Text] [Related]

  • 11. Site-specific action of L-3,4-dihydroxyphenylalanine in the striatum but not globus pallidus and substantia nigra pars reticulata evokes dyskinetic movements in chronic L-3,4-dihydroxyphenylalanine-treated 6-hydroxydopamine-lesioned rats.
    Buck K, Voehringer P, Ferger B.
    Neuroscience; 2010 Mar 17; 166(2):355-8. PubMed ID: 20026252
    [Abstract] [Full Text] [Related]

  • 12. Extent of pre-operative L-DOPA-induced dyskinesia predicts the severity of graft-induced dyskinesia after fetal dopamine cell transplantation.
    García J, Carlsson T, Döbrössy M, Nikkhah G, Winkler C.
    Exp Neurol; 2011 Dec 17; 232(2):270-9. PubMed ID: 21946270
    [Abstract] [Full Text] [Related]

  • 13. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Lundblad M, Usiello A, Carta M, Håkansson K, Fisone G, Cenci MA.
    Exp Neurol; 2005 Jul 17; 194(1):66-75. PubMed ID: 15899244
    [Abstract] [Full Text] [Related]

  • 14. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.
    Lundblad M, Picconi B, Lindgren H, Cenci MA.
    Neurobiol Dis; 2004 Jun 17; 16(1):110-23. PubMed ID: 15207268
    [Abstract] [Full Text] [Related]

  • 15. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Francardo V, Recchia A, Popovic N, Andersson D, Nissbrandt H, Cenci MA.
    Neurobiol Dis; 2011 Jun 17; 42(3):327-40. PubMed ID: 21310234
    [Abstract] [Full Text] [Related]

  • 16. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine.
    Meissner W, Ravenscroft P, Reese R, Harnack D, Morgenstern R, Kupsch A, Klitgaard H, Bioulac B, Gross CE, Bezard E, Boraud T.
    Neurobiol Dis; 2006 Jun 17; 22(3):586-98. PubMed ID: 16531050
    [Abstract] [Full Text] [Related]

  • 17. The GABA uptake inhibitor beta-alanine reduces pilocarpine-induced tremor and increases extracellular GABA in substantia nigra pars reticulata as measured by microdialysis.
    Ishiwari K, Mingote S, Correa M, Trevitt JT, Carlson BB, Salamone JD.
    J Neurosci Methods; 2004 Dec 30; 140(1-2):39-46. PubMed ID: 15589332
    [Abstract] [Full Text] [Related]

  • 18. Unilateral 6-hydroxydopamine lesion of dopamine neurons and subchronic L-DOPA administration in the adult rat alters the expression of the vesicular GABA transporter in different subsets of striatal neurons and in the substantia nigra, pars reticulata.
    Wang H, Katz J, Dagostino P, Soghomonian JJ.
    Neuroscience; 2007 Mar 16; 145(2):727-37. PubMed ID: 17218060
    [Abstract] [Full Text] [Related]

  • 19. Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms.
    Giorgi M, D'Angelo V, Esposito Z, Nuccetelli V, Sorge R, Martorana A, Stefani A, Bernardi G, Sancesario G.
    Eur J Neurosci; 2008 Sep 16; 28(5):941-50. PubMed ID: 18717735
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.